AP Biosciences (ROCO:6945) Cash-to-Debt : 22.75 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AP Biosciences's cash to debt ratio for the quarter that ended in Jun. 2024 was 22.75.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, AP Biosciences could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for AP Biosciences's Cash-to-Debt or its related term are showing as below:

ROCO:6945' s Cash-to-Debt Range Over the Past 10 Years
Min: 9.02 Med: 5011.38 Max: No Debt
Current: 22.75

During the past 4 years, AP Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 9.02. And the median was 5011.38.

ROCO:6945's Cash-to-Debt is ranked better than
66.22% of 1507 companies
in the Biotechnology industry
Industry Median: 6.1 vs ROCO:6945: 22.75

AP Biosciences Cash-to-Debt Historical Data

The historical data trend for AP Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AP Biosciences Cash-to-Debt Chart

AP Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

9.02

AP Biosciences Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial			N/A	No Debt	11.36	9.02	22.75

Competitive Comparison of AP Biosciences's Cash-to-Debt

For the Biotechnology subindustry, AP Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AP Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AP Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AP Biosciences's Cash-to-Debt falls into.

AP Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AP Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	740.017	/	(11.652	+	70.427)
	=	9.02

AP Biosciences's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1741.088	/	(11.653	+	64.869)
	=	22.75

AP Biosciences (ROCO:6945) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

AP Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AP Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AP Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3, Park Street, 17th Floor, Taipei, TWN

Website

https://www.apbioinc.com

AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences Headlines

No Headlines